Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug
Introduction Vestibular migraine (VM) consists of recurrent episodes of vestibular symptoms that are accompanied by migraine in at least 50% of the episodes. The criteria of the Bárány Society include two diagnostic categories: “actual” vestibular migraine and probable vestibular migraine. There is...
Gespeichert in:
| Veröffentlicht in: | European archives of oto-rhino-laryngology 2020-04, Vol.277 (4), p.1013-1021 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1021 |
|---|---|
| container_issue | 4 |
| container_start_page | 1013 |
| container_title | European archives of oto-rhino-laryngology |
| container_volume | 277 |
| creator | Domínguez-Durán, E. Montilla-Ibáñez, M. A. Álvarez-Morujo de Sande, M. G. Domènech-Vadillo, E. Bécares-Martínez, C. González-Aguado, R. Guerra-Jiménez, G. |
| description | Introduction
Vestibular migraine (VM) consists of recurrent episodes of vestibular symptoms that are accompanied by migraine in at least 50% of the episodes. The criteria of the Bárány Society include two diagnostic categories: “actual” vestibular migraine and probable vestibular migraine. There is a wide range of drugs that can be prescribed for the prophylactic treatment of VM, but recommendations for the selection of the most appropriate drug are currently lacking.
Objective
To measure the extent to which the prophylactic treatment of VM reduces vestibular symptoms, headache and the number of crises depending on the diagnostic category of the Bárány Society and the drug used for prophylaxis.
Material and methods
This is a multicenter prospective study. Patients with VM who presented to any of the participating centers and who subsequently met the VM criteria were prescribed one of the following types of prophylaxis: acetazolamide, amitriptyline, flunarizine, propranolol or topiramate. Patients were called back for a follow-up visit 5 weeks later. This allowed the intensity of vestibular symptoms, headache and the number of crises before and during treatment to be compared.
Results
31 Patients met the inclusion criteria. During the treatment, all the measured variables decreased significantly. In a visual analogue scale, the intensity of vestibular symptoms decreased by 45.8 points, the intensity of headache decreased by 47.8 points and patients suffered from 15.6 less monthly crises compared to the period before the treatment. No significant between-group differences were found when patients were divided based on their diagnostic category or the choice of prophylaxis prescribed to them.
Conclusion
The treatment of VM produces a reduction of symptoms and crises with no significant differences based on patients’ diagnostic categories or the choice of prophylaxis prescribed to them. |
| doi_str_mv | 10.1007/s00405-020-05802-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2350347380</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2350347380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-7d56d368884cee954b5d36de3037db8b7a38345b78ecbdae9bd577b45deed7353</originalsourceid><addsrcrecordid>eNp9kT1PIzEQhi3ECQJ3f-CKk0uahcnajp0SIeBOQqLhassfsxtHG2-wdxHp-eE4bKCkssZ-5rHmHUJ-z-FyDiCvMgAHUUENFQgFdSWOyGzOGa-4rBfHZAZLJivOpTwlZzmvAUDwJTshp6wGUCD5jLxdR9Ptcsi0b-iwQopNg24ILxgxf11uU79d7TrzOnEvmIdgx84kugltMiEi9bjF6ENsaR8_enwwbewL6KgzA7Z92lET_cGH2aVg0VOfxvYn-dGYLuOvw3lO_t_dPt38rR4e7__dXD9UjnE5VNKLhWcLpRR3iEvBrSilRwZMequsNEwxLqxU6Kw3uLReSGm58IheMsHOycXkLfM8j2UIvQnZYdeZiP2Ydc0ElJ-YgoLWE-pSn3PCRm9T2Ji003PQ-_T1lL4u6euP9PXe_-fgH-0G_VfLZ9wFYBOQy1NsMel1P6aygfyd9h0XJ5MG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350347380</pqid></control><display><type>article</type><title>Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Domínguez-Durán, E. ; Montilla-Ibáñez, M. A. ; Álvarez-Morujo de Sande, M. G. ; Domènech-Vadillo, E. ; Bécares-Martínez, C. ; González-Aguado, R. ; Guerra-Jiménez, G.</creator><creatorcontrib>Domínguez-Durán, E. ; Montilla-Ibáñez, M. A. ; Álvarez-Morujo de Sande, M. G. ; Domènech-Vadillo, E. ; Bécares-Martínez, C. ; González-Aguado, R. ; Guerra-Jiménez, G.</creatorcontrib><description>Introduction
Vestibular migraine (VM) consists of recurrent episodes of vestibular symptoms that are accompanied by migraine in at least 50% of the episodes. The criteria of the Bárány Society include two diagnostic categories: “actual” vestibular migraine and probable vestibular migraine. There is a wide range of drugs that can be prescribed for the prophylactic treatment of VM, but recommendations for the selection of the most appropriate drug are currently lacking.
Objective
To measure the extent to which the prophylactic treatment of VM reduces vestibular symptoms, headache and the number of crises depending on the diagnostic category of the Bárány Society and the drug used for prophylaxis.
Material and methods
This is a multicenter prospective study. Patients with VM who presented to any of the participating centers and who subsequently met the VM criteria were prescribed one of the following types of prophylaxis: acetazolamide, amitriptyline, flunarizine, propranolol or topiramate. Patients were called back for a follow-up visit 5 weeks later. This allowed the intensity of vestibular symptoms, headache and the number of crises before and during treatment to be compared.
Results
31 Patients met the inclusion criteria. During the treatment, all the measured variables decreased significantly. In a visual analogue scale, the intensity of vestibular symptoms decreased by 45.8 points, the intensity of headache decreased by 47.8 points and patients suffered from 15.6 less monthly crises compared to the period before the treatment. No significant between-group differences were found when patients were divided based on their diagnostic category or the choice of prophylaxis prescribed to them.
Conclusion
The treatment of VM produces a reduction of symptoms and crises with no significant differences based on patients’ diagnostic categories or the choice of prophylaxis prescribed to them.</description><identifier>ISSN: 0937-4477</identifier><identifier>EISSN: 1434-4726</identifier><identifier>DOI: 10.1007/s00405-020-05802-5</identifier><identifier>PMID: 32008074</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Acetazolamide - therapeutic use ; Amitriptyline - therapeutic use ; Analgesics - therapeutic use ; Central Nervous System Agents - therapeutic use ; Flunarizine - therapeutic use ; Head and Neck Surgery ; Humans ; Medicine ; Medicine & Public Health ; Migraine Disorders - complications ; Migraine Disorders - diagnosis ; Migraine Disorders - drug therapy ; Migraine Disorders - prevention & control ; Neurosurgery ; Otology ; Otorhinolaryngology ; Propranolol - therapeutic use ; Prospective Studies ; Topiramate - therapeutic use ; Vertigo - complications ; Vertigo - diagnosis ; Vertigo - drug therapy ; Vertigo - prevention & control ; Vestibular Diseases - complications ; Vestibular Diseases - diagnosis ; Vestibular Diseases - drug therapy ; Vestibular Diseases - prevention & control</subject><ispartof>European archives of oto-rhino-laryngology, 2020-04, Vol.277 (4), p.1013-1021</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-7d56d368884cee954b5d36de3037db8b7a38345b78ecbdae9bd577b45deed7353</citedby><cites>FETCH-LOGICAL-c347t-7d56d368884cee954b5d36de3037db8b7a38345b78ecbdae9bd577b45deed7353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00405-020-05802-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00405-020-05802-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32008074$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Domínguez-Durán, E.</creatorcontrib><creatorcontrib>Montilla-Ibáñez, M. A.</creatorcontrib><creatorcontrib>Álvarez-Morujo de Sande, M. G.</creatorcontrib><creatorcontrib>Domènech-Vadillo, E.</creatorcontrib><creatorcontrib>Bécares-Martínez, C.</creatorcontrib><creatorcontrib>González-Aguado, R.</creatorcontrib><creatorcontrib>Guerra-Jiménez, G.</creatorcontrib><title>Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug</title><title>European archives of oto-rhino-laryngology</title><addtitle>Eur Arch Otorhinolaryngol</addtitle><addtitle>Eur Arch Otorhinolaryngol</addtitle><description>Introduction
Vestibular migraine (VM) consists of recurrent episodes of vestibular symptoms that are accompanied by migraine in at least 50% of the episodes. The criteria of the Bárány Society include two diagnostic categories: “actual” vestibular migraine and probable vestibular migraine. There is a wide range of drugs that can be prescribed for the prophylactic treatment of VM, but recommendations for the selection of the most appropriate drug are currently lacking.
Objective
To measure the extent to which the prophylactic treatment of VM reduces vestibular symptoms, headache and the number of crises depending on the diagnostic category of the Bárány Society and the drug used for prophylaxis.
Material and methods
This is a multicenter prospective study. Patients with VM who presented to any of the participating centers and who subsequently met the VM criteria were prescribed one of the following types of prophylaxis: acetazolamide, amitriptyline, flunarizine, propranolol or topiramate. Patients were called back for a follow-up visit 5 weeks later. This allowed the intensity of vestibular symptoms, headache and the number of crises before and during treatment to be compared.
Results
31 Patients met the inclusion criteria. During the treatment, all the measured variables decreased significantly. In a visual analogue scale, the intensity of vestibular symptoms decreased by 45.8 points, the intensity of headache decreased by 47.8 points and patients suffered from 15.6 less monthly crises compared to the period before the treatment. No significant between-group differences were found when patients were divided based on their diagnostic category or the choice of prophylaxis prescribed to them.
Conclusion
The treatment of VM produces a reduction of symptoms and crises with no significant differences based on patients’ diagnostic categories or the choice of prophylaxis prescribed to them.</description><subject>Acetazolamide - therapeutic use</subject><subject>Amitriptyline - therapeutic use</subject><subject>Analgesics - therapeutic use</subject><subject>Central Nervous System Agents - therapeutic use</subject><subject>Flunarizine - therapeutic use</subject><subject>Head and Neck Surgery</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Migraine Disorders - complications</subject><subject>Migraine Disorders - diagnosis</subject><subject>Migraine Disorders - drug therapy</subject><subject>Migraine Disorders - prevention & control</subject><subject>Neurosurgery</subject><subject>Otology</subject><subject>Otorhinolaryngology</subject><subject>Propranolol - therapeutic use</subject><subject>Prospective Studies</subject><subject>Topiramate - therapeutic use</subject><subject>Vertigo - complications</subject><subject>Vertigo - diagnosis</subject><subject>Vertigo - drug therapy</subject><subject>Vertigo - prevention & control</subject><subject>Vestibular Diseases - complications</subject><subject>Vestibular Diseases - diagnosis</subject><subject>Vestibular Diseases - drug therapy</subject><subject>Vestibular Diseases - prevention & control</subject><issn>0937-4477</issn><issn>1434-4726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kT1PIzEQhi3ECQJ3f-CKk0uahcnajp0SIeBOQqLhassfsxtHG2-wdxHp-eE4bKCkssZ-5rHmHUJ-z-FyDiCvMgAHUUENFQgFdSWOyGzOGa-4rBfHZAZLJivOpTwlZzmvAUDwJTshp6wGUCD5jLxdR9Ptcsi0b-iwQopNg24ILxgxf11uU79d7TrzOnEvmIdgx84kugltMiEi9bjF6ENsaR8_enwwbewL6KgzA7Z92lET_cGH2aVg0VOfxvYn-dGYLuOvw3lO_t_dPt38rR4e7__dXD9UjnE5VNKLhWcLpRR3iEvBrSilRwZMequsNEwxLqxU6Kw3uLReSGm58IheMsHOycXkLfM8j2UIvQnZYdeZiP2Ydc0ElJ-YgoLWE-pSn3PCRm9T2Ji003PQ-_T1lL4u6euP9PXe_-fgH-0G_VfLZ9wFYBOQy1NsMel1P6aygfyd9h0XJ5MG</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Domínguez-Durán, E.</creator><creator>Montilla-Ibáñez, M. A.</creator><creator>Álvarez-Morujo de Sande, M. G.</creator><creator>Domènech-Vadillo, E.</creator><creator>Bécares-Martínez, C.</creator><creator>González-Aguado, R.</creator><creator>Guerra-Jiménez, G.</creator><general>Springer Berlin Heidelberg</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200401</creationdate><title>Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug</title><author>Domínguez-Durán, E. ; Montilla-Ibáñez, M. A. ; Álvarez-Morujo de Sande, M. G. ; Domènech-Vadillo, E. ; Bécares-Martínez, C. ; González-Aguado, R. ; Guerra-Jiménez, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-7d56d368884cee954b5d36de3037db8b7a38345b78ecbdae9bd577b45deed7353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acetazolamide - therapeutic use</topic><topic>Amitriptyline - therapeutic use</topic><topic>Analgesics - therapeutic use</topic><topic>Central Nervous System Agents - therapeutic use</topic><topic>Flunarizine - therapeutic use</topic><topic>Head and Neck Surgery</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Migraine Disorders - complications</topic><topic>Migraine Disorders - diagnosis</topic><topic>Migraine Disorders - drug therapy</topic><topic>Migraine Disorders - prevention & control</topic><topic>Neurosurgery</topic><topic>Otology</topic><topic>Otorhinolaryngology</topic><topic>Propranolol - therapeutic use</topic><topic>Prospective Studies</topic><topic>Topiramate - therapeutic use</topic><topic>Vertigo - complications</topic><topic>Vertigo - diagnosis</topic><topic>Vertigo - drug therapy</topic><topic>Vertigo - prevention & control</topic><topic>Vestibular Diseases - complications</topic><topic>Vestibular Diseases - diagnosis</topic><topic>Vestibular Diseases - drug therapy</topic><topic>Vestibular Diseases - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Domínguez-Durán, E.</creatorcontrib><creatorcontrib>Montilla-Ibáñez, M. A.</creatorcontrib><creatorcontrib>Álvarez-Morujo de Sande, M. G.</creatorcontrib><creatorcontrib>Domènech-Vadillo, E.</creatorcontrib><creatorcontrib>Bécares-Martínez, C.</creatorcontrib><creatorcontrib>González-Aguado, R.</creatorcontrib><creatorcontrib>Guerra-Jiménez, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European archives of oto-rhino-laryngology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Domínguez-Durán, E.</au><au>Montilla-Ibáñez, M. A.</au><au>Álvarez-Morujo de Sande, M. G.</au><au>Domènech-Vadillo, E.</au><au>Bécares-Martínez, C.</au><au>González-Aguado, R.</au><au>Guerra-Jiménez, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug</atitle><jtitle>European archives of oto-rhino-laryngology</jtitle><stitle>Eur Arch Otorhinolaryngol</stitle><addtitle>Eur Arch Otorhinolaryngol</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>277</volume><issue>4</issue><spage>1013</spage><epage>1021</epage><pages>1013-1021</pages><issn>0937-4477</issn><eissn>1434-4726</eissn><abstract>Introduction
Vestibular migraine (VM) consists of recurrent episodes of vestibular symptoms that are accompanied by migraine in at least 50% of the episodes. The criteria of the Bárány Society include two diagnostic categories: “actual” vestibular migraine and probable vestibular migraine. There is a wide range of drugs that can be prescribed for the prophylactic treatment of VM, but recommendations for the selection of the most appropriate drug are currently lacking.
Objective
To measure the extent to which the prophylactic treatment of VM reduces vestibular symptoms, headache and the number of crises depending on the diagnostic category of the Bárány Society and the drug used for prophylaxis.
Material and methods
This is a multicenter prospective study. Patients with VM who presented to any of the participating centers and who subsequently met the VM criteria were prescribed one of the following types of prophylaxis: acetazolamide, amitriptyline, flunarizine, propranolol or topiramate. Patients were called back for a follow-up visit 5 weeks later. This allowed the intensity of vestibular symptoms, headache and the number of crises before and during treatment to be compared.
Results
31 Patients met the inclusion criteria. During the treatment, all the measured variables decreased significantly. In a visual analogue scale, the intensity of vestibular symptoms decreased by 45.8 points, the intensity of headache decreased by 47.8 points and patients suffered from 15.6 less monthly crises compared to the period before the treatment. No significant between-group differences were found when patients were divided based on their diagnostic category or the choice of prophylaxis prescribed to them.
Conclusion
The treatment of VM produces a reduction of symptoms and crises with no significant differences based on patients’ diagnostic categories or the choice of prophylaxis prescribed to them.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32008074</pmid><doi>10.1007/s00405-020-05802-5</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-4477 |
| ispartof | European archives of oto-rhino-laryngology, 2020-04, Vol.277 (4), p.1013-1021 |
| issn | 0937-4477 1434-4726 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2350347380 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Acetazolamide - therapeutic use Amitriptyline - therapeutic use Analgesics - therapeutic use Central Nervous System Agents - therapeutic use Flunarizine - therapeutic use Head and Neck Surgery Humans Medicine Medicine & Public Health Migraine Disorders - complications Migraine Disorders - diagnosis Migraine Disorders - drug therapy Migraine Disorders - prevention & control Neurosurgery Otology Otorhinolaryngology Propranolol - therapeutic use Prospective Studies Topiramate - therapeutic use Vertigo - complications Vertigo - diagnosis Vertigo - drug therapy Vertigo - prevention & control Vestibular Diseases - complications Vestibular Diseases - diagnosis Vestibular Diseases - drug therapy Vestibular Diseases - prevention & control |
| title | Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T03%3A24%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20the%20effectiveness%20of%20the%20prophylaxis%20of%20vestibular%20migraine%20depending%20on%20the%20diagnostic%20category%20and%20the%20prescribed%20drug&rft.jtitle=European%20archives%20of%20oto-rhino-laryngology&rft.au=Dom%C3%ADnguez-Dur%C3%A1n,%20E.&rft.date=2020-04-01&rft.volume=277&rft.issue=4&rft.spage=1013&rft.epage=1021&rft.pages=1013-1021&rft.issn=0937-4477&rft.eissn=1434-4726&rft_id=info:doi/10.1007/s00405-020-05802-5&rft_dat=%3Cproquest_cross%3E2350347380%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350347380&rft_id=info:pmid/32008074&rfr_iscdi=true |